CXCL13/BLC/BCA-1 Antibody (143614) [Unconjugated]

Recombinant Mouse CXCL13/BLC/BCA‑1 (Catalog # 470-BC) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse CXCL13/BLC/BCA‑1 (4 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB470). The ND50 is typically 12-30 µg/mL.

• Reactivity: Mu
• Applications: B/N, ELISA(Cap)
• Clone: 143614
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

CXCL13/BLC/BCA-1 Antibody (143614) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse CXCL13
  Ile22-Ala109
  Accession # O55038
• Specificity: Detects mouse CXCL13 in ELISAs. In ELISAs, this antibody does not cross-react with recombinant human (rh) CXCL13, rmCXCL11/I‑TAC, rmCXCL9/MIG, or rm CXCL12/SDF‑1 alpha.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: CXCL13
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • Neutralization 12-30 ug/mL
  • ELISA Standard (Matched Pair)
• Application Notes: ELISA Detection: Mouse CXCL13/BLC/BCA-1 Biotinylated Antibody (Catalog number BAF470)
  Standard: Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog number 470-BC)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL13/BLC/BCA-1 Antibody (143614) [Unconjugated]

• ANGIE
• ANGIE2
• B cell-attracting chemokine 1
• B lymphocyte chemoattractant
• BCA1
• BCA-1
• BCA1B-cell chemoattractant
• BCA-1CXC chemokine BLC
• B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1)
• BLC
• BLCSmall-inducible cytokine B13
• BLR1L
• B-lymphocyte chemoattractant
• chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)
• chemokine (C-X-C motif) ligand 13
• C-X-C motif chemokine 13
• CXCL13
• SCYB13
• SCYB13B-cell-attracting chemokine 1
• small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Background

CXCL13, also known as B-lymphocyte chemoattractant (BLC) and BCA-1, is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. Mouse CXCL13 cDNA encodes a precursor protein of 109 amino acid residues with a putative leader sequence of 21 residues. Mature mouse CXCL13 shares 64% amino acid sequence similarity with the human protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized CXCL13 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for CXCL13. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

1. Gunn, M.D. et al. (1998) Nature, 391:799.
2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
3. Forster, R. et al. (1996) Cell 87:1037.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL13/BLC/BCA-1 Antibody (MAB470)(6)

Publications using MAB470

• Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith E, Zauderer M CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol, 2015;16(0):6. 2015 [PMID: 25879435]
• Kramer J, Klimatcheva E, Rothstein T CXCL13 is elevated in Sjogren&#039;s syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol, 2013;94(5):1079-89. 2013 [PMID: 23904442] (Neutralization, Mouse)
• Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage. J. Immunol., 2012;189(5):2181-90. 2012 [PMID: 22844119] (IHC-Fr, Mouse)
• Leon B, Ballesteros-Tato A, Browning JL, Dunn R, Randall TD, Lund FE Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. Nat. Immunol., 2102;13(7):681-90. 2102 [PMID: 22634865] (Neutralization, Mouse)
• Zhang M, Yin L, Zhang K, Sun W, Yang S, Zhang B, Salzman P, Wang W, Liu C, Vidyasagar S, Zhang L, Ju S, Okunieff P, Zhang L Response patterns of cytokines/chemokines in two murine strains after irradiation. Cytokine, 2012;58(2):169-77. 2012 [PMID: 22277799] (Luminex Development, Mouse)
• Weisel FJ, Appelt UK, Schneider AM, Horlitz JU, Van Rooijen N, Korner H, Mach M, Winkler TH Unique requirements for reactivation of virus-specific memory B lymphocytes. J. Immunol., 2010;185(7):4011-21. 2010 [PMID: 20739675] (Neutralization, Mouse)

Bioinformatics

• Gene Symbol: CXCL13
• Uniprot:
  • O55038()